Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.
The in vivo properties of an immunoglobulin isotype-switch family of monoclonal antibodies specific for the polysaccharide capsule of Cryptococcus neoformans were examined in a murine model of cryptococcosis. Subclass-switch variants were isolated by sequential sublining of an immunoglobulin G subclass 1 (IgG1)-secreting cell line. Antibodies of the IgG1, IgG2a, and IgG2b isotypes with identical reactivities with cryptococcal polysaccharide were prepared. The antibodies had the distinct biological properties associated with the heavy chains of each respective isotype. The antibodies were used prophylactically or therapeutically in an attempt to alter the course of cryptococcal infection in mice. Survival of mice and a tissue census of the numbers of viable cryptococci in the lung, spleen, and brain were used as indicators of efficacy. Passive immunization with the IgG2a and IgG2b antibodies effected a reduction in the numbers of cryptococci in lung and spleen. Passive immunization with the IgG1 antibody was markedly less effective. Passive immunization had little or no effect on the numbers of cryptococci in brain tissue, regardless of the immunoglobulin isotype. Despite apparent efficacy with regard to reduction in the numbers of yeast cells in the lung and spleen, the results showed no improvement in survival from murine cryptococcosis. Our results indicate that passive immunization produces a modest effect on the course of murine cryptococcosis in tissues other than brain. However, under the experimental conditions used, such treatment does not have a measurable impact on the ultimate outcome of the infection.
Sanford
J E
JE
Department of Microbiology, School of Medicine, University of Nevada, Reno 89557.
Lupan
D M
DM
Schlageter
A M
AM
Kozel
T R
TR
D000818:Animals; D000908:Antibodies, Fungal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000276:immunology; D001921:Brain / Q000382:microbiology; D003453:Cryptococcosis / Q000382:microbiology / Q000517:prevention & control*; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000276:immunology; D007274:Injections, Intraperitoneal; D008168:Lung / Q000382:microbiology; D051379:Mice; D011134:Polysaccharides / Q000276:immunology; D013154:Spleen / Q000382:microbiology
D000908:Antibodies, Fungal; D000911:Antibodies, Monoclonal; D000946:Antigens, Fungal; D007074:Immunoglobulin G; D011134:Polysaccharides